Sino Biopharm presents ERS 2026 preclinical data for oral STAT6 degrader TQH5528

• Sino Biopharmaceutical disclosed preclinical data for TQH5528, an oral STAT6 degrader, already presented at ERS 2026.
• Studies showed strong suppression of the targeted inflammatory pathway in human cell systems, outperforming key comparator therapies in lab testing.
• Non-human primate work indicated rapid, durable STAT6 depletion with no rebound, supporting an oral alternative to injectable biologics.
• A humanized asthma mouse model showed improved airway function with reduced inflammation, supporting further development in allergic diseases.
• In vivo safety studies are ongoing, setting up the next development step toward clinical testing.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sino Biopharmaceutical Limited published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260908-12324666), on September 08, 2026, and is solely responsible for the information contained therein.